The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 340 participants.
Also called NCT05505994
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 340 participants
- Registry
-
NCT05505994
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05505994. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-28 (actual); primary completion 2024-02-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
- Condition
- Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Glucose Metabolism Disorders
- Condition
- Metabolic Disease
- Condition
- Endocrine System Diseases
- Intervention (Drug)
- DWP16001
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- DWP16001 Placebo
- Intervention (Drug)
- Dapagliflozin Placebo
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct05505994- Content hash
de2830b7e1cf4dd3454c108c6b170fab25e18a54c5fd254dda6326d3cd5fdef0